Skip to main content

Table 2 Adverse Events by Dose Level

From: Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma

Grade 1 Adverse Event

N (%)

2.5 μg

25 μg

100 μg

Number of patients

36

11

16

9

Nausea

8 (22)

2 (18)

3 (19)

3 (33)

Fatigue

7 (19)

3 (27)

2* (12)

2 (22)

Headache

7 (19)

3 (27)

2 (12)

2 (22)

Constipation

5 (14)

2 (18)

2 (12)

1 (11)

Asthenia

4 (11)

1 (9)

1 (6)

2 (22)

Pyrexia

4 (11)

1 (9)

1 (6)

1 (11)

Visual change

3 (8)

 

1** (6)

2** (12)

Zoster reactivation

1 (3)

  

1 (11)

  1. * Grade 2, one patient
  2. ** Fleeting, not associated with abnormal ophthalmologic exam